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Summary
Tuberculosis (TB) and human immunodeficiency virus (HIV) can place a major burden on
healthcare systems and constitute the main challenges of diagnostic and therapeutic
programmes. Infection with HIV is the most common cause of Mycobacterium tuberculosis
(Mtb), which can accelerate the risk of latent TB reactivation by 20-fold. Similarly, TB is
considered the most relevant factor predisposing individuals to HIV infection. Thus, both
pathogens can augment one another in a synergetic manner, accelerating the failure of
immunological functions and resulting in subsequent death in the absence of treatment.
Synergistic approaches involving the treatment of HIV as a tool to combat TB and vice versa are
thus required in regions with a high burden of HIV and TB infection. In this context, plant systems
are considered a promising approach for combatting HIV and TB in a resource-limited setting
because plant-made drugs can be produced efficiently and inexpensively in developing countries
and could be shared by the available agricultural infrastructure without the expensive
requirement needed for cold chain storage and transportation. Moreover, the use of natural
products from medicinal plants can eliminate the concerns associated with antiretroviral therapy
(ART) and anti-TB therapy (ATT), including drug interactions, drug-related toxicity and multidrug
resistance. In this review, we highlight the potential of plant system as a promising approach for
the production of relevant pharmaceuticals for HIV and TB treatment. However, in the cases of
HIV and TB, none of the plant-made pharmaceuticals have been approved for clinical use.
Limitations in reaching these goals are discussed.
Introduction
Since its discovery in 1981 in the United States, human
immunodeficiency virus (HIV) had remained a major threat to
global health in unprecedented dimensions (Barre-Sinoussi et al.,
1983). Despite significant progress in HIV/AIDS research, approx-
imately 37 million people are living with HIV (aidsinfo.unaids.org).
HIV has continued to be the leading cause of death in sub-
Saharan Africa and was reportedly responsible for the death of
1.1 million people globally in 2015 (aidsinfo.unaids.org). Current
predictions suggest that more than 5700 people will become
infected with HIV every day, which corresponds to approximately
240 every hour. Moreover, HIV infection can promote the
progression of associated diseases, such as tuberculosis (TB)
(Zetola et al., 2016). Many resource-limited regions with a high
rate of HIV also have a high TB prevalence rate due to lack of
screening tests and efficient treatment (Meintjes et al., 2008;
Murray et al., 2014). TB and AIDS are high-burden diseases that
lead to death worldwide. According to the World Health
Organization (WHO), 6.3 million new cases of TB were reported
in 2016, which is equivalent to 61% of the estimated prevalence
of 10.4 million, and close to 1.7 million deaths from tuberculosis,
including 374 000 deaths among people co-infected with HIV,
were reported in 2016 (http://apps.who.int/iris/bitstream/handle/
10665/259366/9789241565516-eng.pdf;jsessionid=9F217E934C
D2D5155BD5180DE2FC75E9?sequence=1). TB is the major single
cause of death in regions with HIV (Corbett et al., 2003) and is
associated with nearly 26% of AIDS-related deaths (Getahun
et al., 2010), 99% of which occur in developing countries (Collins
et al., 2002). In this regard, India and South Africa are countries
with the highest burden of HIV-associated TB (Department of
Health, 2014; World Health Organization, 2016).
The Mtb–HIV relationship is attributed both to the suppression
of host immune systems by HIV (Schluger and Rom, 1998) and to
environmental risk factors allocated by the two diseases (Drob-
niewski et al., 2005), which complicates their diagnosis and
treatment and places an immense burden on public health
systems and productivity, particularly in developing countries with
large populations of co-infected people (Pawlowski et al., 2012).
Both pathogens, HIV and Mtb, potentiate the severity of each
other’s symptoms, increasing the deterioration of the immune
system and causing premature death in the absence of treatment.
HIV is considered one of the strongest risk factors for the
exacerbation of TB infection to active disease and accelerates the
risk of latent TB reactivation by 20-fold (Pawlowski et al., 2012),
and similarly, TB has been indicated to intensify HIV incidence
(Modjarrad and Vermund, 2010).
Although some modest improvements, such as increases in
active antiretroviral therapy (ART) coverage and cotrimoxazole
preventative therapy, have been obtained among patients with
HIV-TB, it remains a complex challenge in extremely high-burden
settings. Moreover, co-morbidity decreases the efficiency of both
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anti-TB and antiretroviral drugs, and co-administration can
augment the risk of drug-related toxicity as well as drug
resistance. Because the prevalence of both diseases contributes
to the mortality rate in poor countries, it can disproportionately
affect people’s ability to afford therapy. This is particularly related
to the production costs of biopharmaceuticals through expensive
fermenter-based systems and further downstream processes (Ma
et al., 2003; Stoger et al., 2005) as well as the expensive
requirements for cold chain storage and transport (Chan and
Daniell, 2015; Kwon et al., 2013a).
Considering the aforementioned facts, efficient alternatives to
combat the threat of TB and HIV incidence are urgently
required, and in this context, plant system offers potential
capacities. This review elaborates on plant molecular pharming
and different medicinal plants that are used in the treatment of
HIV and TB infection. Because the recent armamentarium
against HIV and TB exhibits remarkable limitations ranging from
toxicity to extensive and expensive therapy, the potential of
plants in terms of safety and cost-effective expression platforms
as well as the production of plant natural compounds with anti-
TB and HIV potential will contribute to further eradication and
management of HIV and TB, especially in extremely high-burden
settings. The knowledge obtained regarding the use of molec-
ular pharming and medicinal plants in HIV and TB treatment as
well as the promising results obtained in different studies shows
that plants are efficient, convenient and affordable platforms for
the production of biopharmaceuticals for use as an
immunomodulatory agent or a supplement for the treatment
of TB and HIV as well as HIV-TB co-infection. However, in the
cases of HIV and TB, none of the plant-made pharmaceuticals
have been approved for clinical use. Limitations in reaching
these goals are discussed.
Routes of HIV and TB infection
HIV transmission is initiated by sexual relationships via virus
exposure at the mucosal epithelium of the vagina or rectum, by
maternal–infant exposure and by percutaneous inoculation (Shaw
and Hunter, 2012). However, the precise transmission mechanism
is complicated and has not been fully elucidated, and different
strategies are involved. It is globally understood that macro-
phages, T cells and dendritic cells are favourable destinations for
HIV. HIV invades the CD4 cells of the immune system and
employs the machinery of the CD4 cells to multiply and spread
throughout the body. Virus protein gp120 binding to the CD4
receptor initiates the cascade of conformational changes in gp
120 that enable gp120 to interact with the host cell co-receptor.
Engagement of the co-receptor induces a further conformational
change in the envelope glycoprotein that leads to the induction of
gp41-mediated virus–host cell membrane fusion. The virus
progressively starts its infection through transformation of the
viral RNA genome into a pro-viral DNA. The integrated provirus is
transcribed by the host RNA polymerase II into full-length viral
RNA, which can subsequently be individually or multiple spliced
(Shors, 2011). The synthesized viral RNA is then transported from
the nucleus to the cytoplasm for translation to gRNA for
packaging. The host cellular machinery generally inhibits the
transport of single and unspliced viral RNA species, and to
overcome this obstacle, HIV-1 synthesizes the Rev protein, which
binds to the Rev response element (RRE) and to the chromoso-
mal maintenance 1 (CRM1)/RanGTP nuclear export complex
(Mailler et al., 2016). After export from the nucleus and mRNA
translation, a proteolytic processing undertaken by the viral
protease that occurs during or quickly following the budding of
the immature particle (Konnyu et al., 2013) leads to synthesis of
the structural proteins that are critical for morphological
rearrangements of the viral particle (Bell and Lever, 2013)
(Figure 1).
TB is an airborne infection caused by the bacillus Mtb, which is
transmitted via the inhalation of infectious droplet nuclei carried
by the fluids expelled by coughing, sneezing or shouting individuals
infected with pulmonary or laryngeal TB disease (https://
www.cdc.gov/tb/education/corecurr/). Transmission occurs when
droplet nuclei containing Mtb are inhaled by an individual, and the
droplet nuclei pass from the mouth, the nasal and upper
respiratory tract, and bronchi to arrive at the alveoli of the lungs
(https://www.cdc.gov/tb/education/corecurr/). Professional phago-
cytic cells in the lungs, such as dendritic cells, macrophages,
monocytes and neutrophils, can be recruited by the progressive
growth of the mycobacterial population and develop into early
granulomas (Kang et al., 2011; Wolf et al., 2007).
Obtaining an in-depth understanding of the immune response
against Mtb is a major challenge to the lives and health of
susceptible human populations. Based on this challenge, the
available evidence indicates that although most humans exper-
imentally establish sufficient immune responses after infection,
these immune responses do not completely eliminate the
bacteria. However, immunological, epidemiological and genetic
studies have demonstrated that both T-cell-mediated immunity
and innate immunity are involved in tuberculosis, and different T-
cell subsets, cellular receptors and humuoral factors are required
(van Crevel et al., 2002).
Drugs used to combat HIV and TB co-infection
The emergence of highly ART has remarkably decreased both the
mortality and the morbidity caused by HIV (Hogg et al., 1998).
Among HIV-infected people, TB is considered one of the most
potent infections, leading to death in resource-limited areas
(Corbett et al., 2003). Although both ART and anti-tubercular
treatment (ATT) have been demonstrated to increase the survival
of co-infected individuals, establishing a precise ART regimen
remains controversial due to many concerns of unfavourable drug
interactions.
Efavirenz and nevirapine, which are classes of non-nucleoside
reverse transcriptase inhibitors (NNRTIs), are generally recom-
mended for individuals infected with HIV and TB. Rifamycins,
especially rifampicin (RMP), in combination with isoniazid (INH),
ethambutol (EMB) and pyrazinamide (PZA), are key medications
for the treatment of TB because RMP is a potent inducer of the
cytochrome P450 enzyme system, which leads to improved
clearance of NNRTIs (Jiang et al., 2014). Rifamycins provide
inducing effects on phase I and II drug-metabolizing enzymes and
transporters (Rabie et al., 2017). However, ART is often metab-
olized by a rifamycin-induced cytochrome P450 enzyme system or
might prevent specific enzyme activity caused by drug–drug
interactions with rifamycins, which may lead to adverse modifi-
cations in the pharmacokinetic and pharmacodynamic character-
istics of the drug. Drug interactions can modify the absorption,
transport, distribution, metabolism or excretion of drug which
may result in viral resistance or serious toxic effects leading
treatment failure (Abdool Karim et al., 2010). In this context, the
emergence of viral resistance to antiretroviral (ARV) drugs is a
common cause of ART failure.
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Natural sources of plant metabolites with
anti-HIV and TB activity
According to archaeological excavations, it is likely that the
humans recognized and used medicinal plant as long as
60 000 years ago (Fabricant and Farnsworth, 2001), representing
the potential of plant medicine in production of valuable cocktail
secondary metabolites for our healing and health care (Sharifi-
Rad et al., 2018). Additionally, based on this record we can say
that humans have been involved for thousands of years in a vast
‘clinical trial’ with medicinal plants as they have tested their
efficacy. Moreover, historically, oral administration of plant-made
medicines through direct using of plant tissues or by the
preparation of crude extracts considered as a great advantages
as these strategies are both simple and inexpensive as well as
remove disadvantages related to syringe-based injection or other
required invasive procedures.
Plant secondary metabolites are involved in the adaptation of
plants to their environment, and most of these metabolites are
involved in plant defence mechanisms against pathogen invasion
and abiotic stress (Habibi et al., 2017b). These valuable com-
pounds could be extracted from different parts of plants, such as
leaves, shoots, roots and flowers, and investigated for their
potential as anti-HIV and anti-TB drugs. Phenolic compounds,
flavonoids, triterpenes, coumarins and alkaloids are examples of
prominent natural products with anti-HIV and TB activity (Kura-
pati et al., 2016). A condensed summary of the most active plant
secondary metabolites against HIV and TB is provided in Tables 1
and 2, respectively.
Medicinal plants for the treatment of AIDS
Although antiretroviral therapy allows patients living with HIV to
live longer and maintain their HIV symptoms at undetectable
levels, the cost of the medications used in highly active
antiretroviral therapy (HAART) is especially high for those living
in developing countries, and these medications also have other
drawbacks, such as viral reservoirs and drug resistance due to
lifelong use, side effects, including nausea, headaches, poor
appetite and stomach cramps, and severe toxicities, such as
cardiovascular disease, neurotoxicity, kidney disease, hypersensi-
tivity reactions, liver damage, insulin resistance, diabetes and
body fat redistribution (Williams-Orlando, 2017). These disad-
vantages of HAART have encouraged a search for new better
(safe, effective and cheap) anti-HIV agents in plant species.
Medicinal plants offer a number of advantages that make them
a promising alternative to antiretroviral therapy or as a comple-
mentary treatment to decrease the drawbacks associated with
HAART (Salehi et al., 2018). In comparison with HAART, medic-
inal plants are more attractive because they are less expensive and
exhibit low side effects. Medicinal plants block HIV at various
stages of the viral life cycle. Some of these plants decrease viral
entry into plasma, improve immune function and boost the
quality of life, and if administered alone or in combination with
highly active antiretroviral therapy, some plants relieve the side
effects of biomedical drugs (Chu and Liu, 2011), potentiate an
antioxidant status, augment or sustain CD4 T cells, reduce chronic
inflammation and boost neuroprotection (Williams-Orlando,
2017). Several anti-HIV herbs are being investigated in clinical
trials (Table 3) or are being used for the treatment of individuals
infected with HIV.
Considering the above advantages, the World Health Organi-
zation (WHO) has strongly recommended the evaluation of
ethno-medicines and other natural compounds for anti-HIV
activity because they offer efficient and tremendous therapeutic
properties (WHO, 1989a,b). In this context, those of compounds
which interfere with different stage of HIV virus are ideal. The
natural agents including calanolides (coumarins), baicalin (flavo-
noid), polycitone A (alkaloid), ursolic and betulinic acids
Figure 1 schematic presentation of HIV life
cycle. (a) HIV attachment to CD4 antigen and a
specific chemokine receptor. (b) Virus fusion with
the cell membrane and entry of the virion core
into the cell. (c) Release of viral RNA and core
proteins and their transport into the nucleus. (d)
Formation of double-stranded DNA by reverse
transcriptase. (e) Transport of double-stranded
viral DNA into the cell nucleus. (f) Integration of
viral DNA into cellular DNA. (g) Synthesis of viral
RNA by RNA polymerase II and production of RNA
transcripts with shorter spliced RNA (h) and full-
length genomic RNA (j). (h) Transport of shorter
spliced RNAs to the cytoplasm and the production
of several viral proteins that are then modified in
the Golgi apparatus of the cell (i). (j) Transport of
full-length genomic RNAs into the cytoplasm (k).
(l) Assembly, budding and maturation of new
virions. (m) Release of mature virus.
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Table 1 Summarized plant active compounds against HIV
Compound
group Agent Mechanism of action EC50 IC50 Plant system Reference
Alkaloids Papaverine Inhibits HIV replication and
decreases HIV protein
production
– 10 lg/mL Papaver
somniferum L.
(Papaveraceae)
Turano et al. (1989)
Emetine Inhibits HIV-1 replication by
interfering with reverse
transcriptase activity
0.03 lM – Psychotria
ipecacuanha
Chaves Valadao et al.
(2015)
Corydine Inhibits HIV-1 reverse
transcriptase enzyme activity
356.8 lg/mL Croton
echinocarpus
Ravanelli et al. (2016)
Norisoboldine 53.7 lg/mL
Buchapine Inhibits the cytopathogenic
effects of HIV-1
0.94 lM – Evodia
roxburghiana
McCormick et al.
(1997)
Matairesinol Inhibits HIV replication 0.037 lM – Symplocos
setchuenensis
Ishida et al. (1997)
Harman 210 lM –
O-Demethylbuchenavianine Not defined 0.66 lM Buchenavia capitata Beutler et al. (1992)
Nitidine chloride Inhibits HIV-1 reverse
transcriptase enzyme activity
– 49 lg/mL Toddalia asiatica Tan et al. (1991)
Fagaronine chloride – 10 lg/mL
Schumannificine Irreversibly binds to gpl20 1.6 lM Schumanniophyton
magnificum
Houghton et al.
(1997)
Coumarins Suksdorfin Inhibits HIV replication 2.6 
2.1 lM
Lomatium suksdorfii
(S. Watson) J.M.
Lee et al. (1994)
Calanolide A Inhibits HIV replication – 0.32 lM C. cordato-
oblongum
Dharmaratne et al.
(1998)
Cordatolide A Inhibits HIV replication – 19.3 lM C. cordato-
oblongum
Dharmaratne et al.
(1997)Cordatolide B – 11.7 lM
Terpenes Uvaol Inhibits HIV-1 protease – 5.5 lM Crataegus
pinnatifida
Min et al. (1999)
Ursolic acid – 8 lM
Maslinic acid Inhibits HIV-1 protease – – Geum japonicum Xu et al. (1996)
Celasdin B Anti-HIV replication activity – 0.8 lg/mL Celastrus hindsii Kuo and Kuo (1997)
Garciosaterpene A
Garciosaterpene B
Inhibits HIV-1 reverse
transcriptase
– 5.8 lg/mL Garcinia speciose Rukachaisirikul et al.
(2003)
Suberosol Not defined 33 lg/mL – Polyalthia suberosa Li et al. (1993)
Tripterifordin Anti-HIV replication activity 1 lg/mL – Tripterygium
wilfordii
Chen et al. (1992)
Lancilactone C Inhibits HIV replication 1.4 lg/mL – Kadsura lancilimba Chen et al. (1999)
Flavonoid Baicalin Anti-HIV-1 activity as a non-
nucleoside reverse
transcriptase inhibitor
Scutellaria
baicalensis
Li et al. (2000)
6,8 Diprenylaromadendrin Anti-HIV activity in an XTT-
based, whole-cell screen
2.1 lg/mL 4.7 lg/mL Monotes africanus Meragelman et al.
(2001)6,8-Diprenylkaempferol 2.4 lg/mL 5.8 lg/mL
Lonchocarpol A 1.3 lg/mL 2.7 lg/mL
Quercetin 3-O-(2-galloyl)
a-L-arabinopyranose
Inhibit integrase activity of HIV-1 – 18.1 lg/mL Acer okamotoanum Kim et al. (1998)
Morelloflavone Inhibition of the polymerase of
HIV-1
6.9 lM – Rhus succedanea Lin et al. (1997)
Robustaflavone – 65 lM
Hinokiflavone – 65 lM
Alnustic acid methyl ester Inhibition of HIV-1 protease 15.8 lM Alnus firma Yu et al. (2007)
Quercetin Inhibition against HIV-1 reverse
transcriptase
– 60 lM A. firma Yu et al. (2007)
Quercitrin – 60 lM
Myricetin 3-O-beta-D-
galactopyranoside
– 60 lM
Xanthohumol Induce cytopathic effects, the
production of viral p24 antigen
20.74l/mL – Hops Humulus
lupulus
Wang et al. (2004)
Phenolics Lithospermic acid Integrase inhibitors – 2 lM Salvia miltiorrhiza Abd-Elazem et al.
(2002)Lithospermic acid B – 6.9 lM
Corilagin, quercetin Inhibitory against human
immunodeficiency virus (HIV)
reverse transcriptase
– 20 lM Chamaesyce
hyssopifolia
Lim et al. (1997)
3-O -b-D-glucopyranoside – 50 lM
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(triterpenes) and lithospermic acid (phenolic compound) have
indicated efficient activity against HIV; however, most of these
investigations are in vitro, and a too few investigations have been
carried out in vivo or in human studies (Salehi et al., 2018).
Different assays and protocols have been developed for prelim-
inary screening of natural compounds against HIV. HIV-1 repli-
cation inhibition assays could be performed with simple cell-based
assays including MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (Weislow et al., 1989) or XTT: sodium 3-[1-
(phenylamino)-carbonyl]-3,4-tetrazoliumbis(4-methoxy-6-nitro)
benzene-sulphonic acid hydrate assays (Mahmood, 1995) and
HIV p24 expression using human T-cell lines (Lee-Huang et al.,
1991). Target specific analysis could be carried out by assessment
of compound effect on HIV gp120/CD interaction, reverse
transcriptase inhibition assay (using radio-labelled nucleotide,
non-radioactive ELISA method and RNase H activity), integrase
inhibition assay (using radio-labelled oligonucleotide substrate or
by using non-radioactive ELISA) and protease inhibition assay by
specific techniques such as ELISA, liquid scintillation counting,
fluorometric, spectrophotometric and HPLC-based methods.
However, further pharmacological and toxicological analyses of
crude extract and/or isolated compound are required.
As described above, the concomitant use of medicinal plants
with conventional therapy is a promising approach to relieve the
adverse side effects of antiretroviral therapy and to improve the
therapeutic properties of the administered drugs. In this context,
there are considerable reports on the co-administration of herbal
medicine with conventional therapy. Huang et al. (2007)
reported that resin components of Dracaena cochinchinensis
can relieve the adverse reaction of HAART drugs and boost the
efficacy of HAART. Zhao et al. (2006) demonstrated the enhanc-
ing effects of TCM on HAART, which involve inhibition of viral
rebound and maintenance of immune functions after HAART is
stopped. These researchers also indicated a significant improve-
ment in a range of symptoms and signs associated with HAART,
such as diarrhoea, fatigue, nausea, skin rash and anorexia.
Additionally, the co-administration of herbal medicine with
antiretroviral drugs could adversely enhance drug bioavailability
and therapeutic properties by modifying the absorption of the co-
administered drug (Brown et al., 2008). In this context, interference
of the active transport process during efflux by the co-adminis-
tered medicinal plant is considered a factor that may affect drug
absorption (Balayssac et al., 2005). Brown et al. (2008) indicated
that water extracts of Hypoxis hemerocallidea and l-canavanine (a
constituent of Sutherlandia frutescens), when taken concomi-
tantly, remarkably potentiate the bioavailability of nevirapine by
improving the transport of nevirapine across human intestinal
epithelial cells.
However, the use of medicinal plants concomitantly with
HAART should be further clinically evaluated because there is a
potential risk of herb–drug interaction (HDI) (Chen et al., 2011),
which may significantly exacerbate the health status of the
patients if not detected early during treatment. Despite the wide
use of medicinal plants among patients being administered
Table 1 Continued
Compound
group Agent Mechanism of action EC50 IC50 Plant system Reference
1,3,4,6-tetra-O -galloyl-b-D-
glucopyranose
– 86 lM
Repandusinic acid Inhibition of HIV-1 reverse
transcriptase
– 2.5 lM Phyllanthus niruri Ogata et al. (1992)
Monopotassium salt of
isomeric caffeic acid
Inhibition of HIV replication 2.8 lg/mL – Arnebia euchroma Kashiwada et al.
(1995)
Monosodium salt of isomeric
caffeic acid
4 lg/mL –
Vismiaphenone D Inhibition of the HIV-1 protease 11 lg/mL V. cayennensis Fuller et al. (1999)
Peltatol A Not defined – 35 lg/mL Pothomorphe
peltata
Gustafson et al.
(1992)
Lignans Kadsulignans M Inhibition of HIV reverse
transcriptase activity
6.03 9 10-6 M 1.19 9 10-4 M K. Coccinea Liu and Li (1995)
Olignan A HIV-1 reverse transcriptase (RT)
inhibitory
– 60.4 lg/mL Anogeissus
acuminata
Rimando et al. (1994)
Olignan B – 1.072 lg/mL
Gomisin Inhibitors of HIV replication 0.006 l/mL – K. interior Chen et al. (1997)
(+/-)-Gomisin M1 Inhibitory against HIV replication 0.65 lM 44.5 lM Schisandra
rubriflora
Chen et al. (2006)
Rubrisandrins A 11.3 lM >64 lM
Schisanhenol 5.7 lM 42 lM
Wilsonilignan A Preventing the cytopathic
effects of HIV-1
3.26 lg/mL – S. wilsoniana Yang et al. (2010)
Wilsonilignan B 6.18 lg/mL –
Wilsonilignan C 2.87 lg/mL –
Aponins Actein Activity against HIV replication 0.375 lg/mL – Cimicifuga
racemosa
Sakurai et al. (2004)
Sulphated
polysaccharide
Prunellin Interfere with HIV-1 virion
binding to permissive cells by
blocking CD4 interactions
– 1.1 lg/mL Prunella vulgaris L Oh et al. (2011)
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HAART, the available information on their pharmacokinetic and
pharmacodynamic properties is scarce (He et al., 2011; Thomford
et al., 2015), and further studies evaluating these properties in
humans are imperative. There is substantial evidence indicating
that the co-administration of herbal medicine with conventional
therapy results in clinical complications due to HDIs (Chen et al.,
2011; Huang et al., 2008; Thomford et al., 2015). Although the
prediction of drug interactions during drug development is
challenging, the FDA guidelines, methodologies and recommen-
dations related to drug interactions, particularly cytochrome
P450-based and transporter-based drug interactions, could be
effective (Huang et al., 2008). The FDA’s current understanding
of drug interactions is available online (http://www.fda.gov/cde
r/drug/drugInteractions/default.htm). Moreover, to decrease
HDIs, phytochemical profiling and subsequent mechanistic studies
of the co-administered medicinal plants should be performed to
identify the compounds involved in HDIs. Equally important is the
regulation of effective drug dose in plant materials or formula-
tions. Standardization of plant medicinal formulations is a key
factor in order to analyse drug quality, based on the concentra-
tion of their active principles, physical, chemical, phytochemical,
standardization and in vitro, in vivo parameters. Due to genetic
environmental and cultural factors, the ingredients variability
occurs in herbs or herbal preparations which make the use of
herbal medicines more complicated. For instance, the availability
and quality of the raw materials are frequently challenging, the
active principles are diverse or may be unknown, and quality of
different batches of preparation may be difficult to control and
ascertain (Folashade et al., 2012). Moreover, there is no official
regulatory standard for cultivation, preparation of herbal medici-
nes and clinical evaluation.
Medicinal plants and their secondary metabolites for
treatment of TB
Despite remarkable progress in combating TB prevalence, the
disease is continuing to spread worldwide, which has led to
serious global health challenges: more than 10.4 million patients
living with TB and 1.8 million deaths were reported in 2015
(Nguyen, 2016; WHO, 2015, 2016). The continued incidence of
TB stems from the fact that the pathogen can survive against host
defence mechanisms due to induced multidrug resistance (MDR-
TB), extensive drug resistance (XDR-TB) and total drug resistance
associated with the inappropriate use of anti-TB medications
during treatment for other diseases, such as diabetes mellitus and
HIV (WHO, 2015). MDR-TB strains are strongly persistent against
both isoniazid and rifampicin medication and caused over
480 000 new infections and 210 000 deaths in 2013 (Nguyen,
2016). XDR-Mtb strains are also resistant to quinolones and other
second-line drugs because some clinical strains are resistant to all
available antibiotics (Adhvaryu and Vakharia, 2011; Mishra et al.,
2015). In this case, their morbidity is rapidly increasing in regions
with high HIV prevalence.
Under these circumstances, the discovery and production of
newer anti-tuberculosis compounds that potentially eliminate
antibiotic resistance in terms of MDR-TB and XDR-TB and boost
the immune system against Mtb is needed to tackle global TB
prevention. Moreover, the development of new agents that
target the establishment of mycobacterial dormancy in human
macrophages or prevent bacterial virulence factors that interfere
with the signalling pathways of host cells and affect immunity
and cause pathogen resistance should be considered the main
future research directions (Koul et al., 2011).T
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Table 3 Ongoing and completed clinical trials of medicinal plants for their anti-HIV activity
Medicinal plant and
country Study design Purpose Study phase
Recruitment
status
ClinicalTrials.gov
number
Hypoxis obtuse,
USA
18 participants, single group
assignment, pharmacokinetics
single-arm, open label
To evaluate drug interactions between an
African potato (Hypoxis obtuse) and the
antiretroviral agents lopinavir/ritonavir
(Kaletra).
Phase I Completed NCT01227590
A. annua L and
Moringa oleifera,
Uganda
282 participants, randomized,
double (participant, care
provider), parallel assignment.
To study the effect of A. annua L and
Moringa oleifera leaf powder on CD4 cell
count and other immunological indices in
HAART-treated HIV patients.
Not applicable Not yet recruiting NCT03366922
Echinacea
purpurea, Spain
15 participants, non-
randomized, single group
assignment, two arms, open
label.
To evaluate drug interactions between
E. purpurea and the protease inhibitor
etravirine.
Phase I Completed NCT01347658
E. purpurea, Spain 15 participants, non-
randomized, single group
assignment, two arms, open
label.
To assess drug interactions between one
medicinal herb widely used by HIV-
infected patients: Echinacea sp. and the
protease inhibitors darunavir/ritonavir.
Phase 4 Completed NCT01046890
Moringa leifera,
Zimbabwe
19 participants, observational
model: case-crossover, time
perspective: prospective.
To characterize the interaction between
herbal M. oleifera and the antiretroviral
drugs nevirapine and efavirenz.
- Completed NCT01410058
Traditional Chinese
Medicine, USA
40 participants, parallel
assignment.
To compare traditional Chinese medicine
with standard antibiotic therapy
consisting of pseudoephedrine (Sudafed)
plus the amoxicillin/clavulanate
potassium combination (Augmentin) in
reducing symptoms and recurrence of
acute HIV-related sinusitis.
Not applicable Completed NCT00002149
Triptolide wilfordii,
China
15 participants, non-
randomized single group
assignment, two arms, open
label.
To evaluate the effects and side effects of
ARV treatment in Chinese patients in
acute HIV-1 infection and to evaluate the
impact of T. wilfordii on the HIV-1
reservoir.
Phase 3 Unknown NCT02219672
T. wilfordii, China 150 participants, randomized,
crossover assignment, two
arms.
To evaluate the impact of T. wilfordii on T-
cell immune activation and inflammation
biomarkers in HIV-infected
immunological non-responders.
Phase 1 and Phase 2 Unknown NCT01817283
T. wilfordii, China 300 participants, randomized,
parallel assignment, two arms,
double-blinded, placebo-
controlled study.
To explore the efficacy and safety of
T. wilfordii on viral suppression, immune
recovery and immune activation
biomarkers in the treatment of patients
with na€ıve HIV-1 infection.
Phase 3 Not yet recruiting NCT03403569
Euphorbia kansui,
USA
9 participants, non-randomized,
single group assignment, three
arms, open label.
To evaluate the safety and efficacy of
E. kansui extract in HIV-infected
antiretroviral therapy (ART)-suppressed
individuals.
Phase 1 Not yet recruiting CT02531295
T. wilfordii Hook F
(TwHF), China
23 participants, parallel, non-
randomized, two arms, open-
label trial.
To evaluate the impact of TwHF on T-cell
immune activation and immune response
activation in HIV-infected immunological
non-responders.
Not applicable Completed NCT02002286
TwHF, China 60 participants, randomized,
parallel assignment, two arms.
To evaluate the efficacy and safety of
TwHF in immune non-responders with
HIV-1 infection.
Phases 1 and 2 Unknown NCT01666990
Immunity 1
(Fuzheng 1), China
60 participants, randomized,
parallel assignment, two arms,
double-blind, placebo-
controlled trials.
To evaluate the effect of Immunity 1
(Fuzheng 1) on immune reconstitution in
HIV patients.
Not applicable Unknown NCT00974285
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In this regard, medicinal plants are being investigated as novel
resources for the production of valuable and active secondary
metabolites for the treatment of TB (Sharifi-Rad et al., 2017).
Different medicinal plants have been reported to exert potential
effects against latent and/or drug-resistant forms of TB, intracel-
lular TB, dormant bacilli (Table 2), and against HIV-TB co-
infection, and some of them also exhibited immunomodulatory
effects (Gupta et al., 2017).
Synergistic antimycobacterial effects of plants
Due to administration of two or more drugs concomitantly leads
to the emergence of resistant circulating strains and the devel-
opment of new drugs is a long process, it would be useful to
identify adjuvants capable of boosting the efficacy of antibiotics
against resistant strains. Mutations in the genomic targets of
drugs, the production of drug-modifying and drug-inactivating
enzymes, low cell wall permeability and efflux-related mecha-
nisms have been identified as the main mechanism of resistance
in Mtb (Gupta et al., 2006). In this context, the susceptibility of
microbes to antibiotics is influenced by the use of natural
products (Ge et al., 2010). In vitro synergistic effects induced by a
combination of plant agents with antibiotics have been investi-
gated (Table 4). The available reports on the synergy between
plant compounds and antibiotics against Mtb strains present the
feasible impact of these agents on restoring the susceptibility of
resistant bacteria to antibiotics. A checkerboard synergy assay has
been applied for the determination of synergistic activity and is
generally defined by fractional inhibitory concentration index
(FICI) values of ≤ 0.5, antagonism by FICI values of > 4.0 and no
interaction by FICI values from 0.5 to 4.0 (Odds, 2003). Finally, it
should be noted that the validation of efficacy and safety of plant
compounds as anti-tuberculosis agents takes a long time and,
then in this case, more high-level randomized clinical trials are
urgently needed (Sharifi-Rad et al., 2017).
Search for plants with both anti-TB and anti-HIV activity
Because the number of CD4 + lymphocytes is decreased in
people infected with HIV, these individuals are also susceptible to
acquiring or reactivating tuberculosis disease (Flynn and Chan,
2001). The treatment programmes for patients co-infected with
HIV/TB encounter some barriers, such as intolerance, contraindi-
cations and poor adherence to medication regimes due to large
number of medications. For example, for patients infected with
HIV virus, the administration of 20 pills per day (1 non-
nucleoside + 1 nucleoside type) is recommended for HAART,
and 10–12 pills are recommended as monotherapy for TB (Dean
et al., 2002). Additionally, HIV-1 protease inhibitor drugs can
neutralize the effect of rifampin administered for TB treatment
(Driver et al., 2001; Schwander et al., 1995). Moreover, overlap-
ping toxicity profiles may cause interruption or alteration of TB
and HIV regimens which potentially resulting in microbiological or
virological failure (Dean et al., 2002). Therefore, the discovery
and development of new agents with remarkable activity against
HIV and Mtb are urgent requirements. In this regard, the
isolation, purification and identification of valuable secondary
metabolites from medicinal plants could be a promising, efficient
and affordable approach for the control and treatment of both
targets.
Naturally, anti-HIV(+)-calanolide A, a secondary metabolite
extracted from C. lanigerum, exhibited activity against all strains
of Mtb (MIC: 8–16 lg/mL) (Xu et al., 2004). This compound
induced rapid prevention of RNA and DNA synthesis followed by
an inhibition of protein synthesis. Moreover, the ethanol extract
of Annona muricata showed inhibitory activity against both Mtb
with an MIC value of 125 lg/mL and HIV-1 integrase activity with
IC50 < 100 lg/mL (van de Venter et al., 2014). However,
A. muricata extract exhibited cytotoxicity against Chang liver
and HepG2 cells with IC50 values of 30 and 77 lg/mL,
respectively. Recently, the effect of Mexican Julianaceae and
Clusiaceae crude plant extracts against both HIV-RT and Mtb
H37Rv has been investigated (Gomez-Cansino et al., 2015).
Among 14 Julianaceae species, three species, Amphipterygium
glaucum, A. molle and A. simplicifolium, exhibited inhibitory
activity against Mtb with IC50 values of 1.87–2.35 lg/mL and
against HIV reverse transcriptase with IC50 values of 59.25–
97.83 lg/mL. Among this group, A. adstringens was reported as
a promising source of anti-TB agents because the stem bark
extract prevented 95% of Mtb growth at a concentration of
50 lg/mL. Moreover, three species of Clusiaceae, namely Vismia
baccifera, Calophyllum brasiliense and Vismia Mexicana, inhibited
Mtb with IC50 values of 3.02–3.64 lg/mL and HIV reverse
transcriptase with IC50 values of 26.24–35.17 lg/mL (Gomez-
Cansino et al., 2015). Among these three most active plants,
C. brasiliense is more interesting because its leaves synthesize
dipirano-tetracyclic coumarins, such as inophyllums, calanolides
A, B and C, and soulatrolide, which were previously shown to
exhibit activity against HIV-1 reverse transcriptase (Gurib-Fakim,
2006) and M. tuberculosis (Xu et al., 2004).
Table 3 Continued
Medicinal plant and
country Study design Purpose Study phase
Recruitment
status
ClinicalTrials.gov
number
Immunity 1 and
Immunity 3
(Fuzheng 1 and 3):
composed of herbs
with tonic and
detoxification
functions, China
180 participants, randomized,
parallel assignment, double-
blind, placebo-controlled
clinical trials.
To evaluate the effect of the combination
of traditional Chinese medicine (TCM)
and highly active antiretroviral therapy
(HAART) on immune reconstitution in
HIV/AIDS patients.
Not applicable Unknown NCT00974519
Immunity 2
(Fuzheng 2), China
180 participants, randomized,
parallel assignment, two arms.
To research the effect of TCM on immune
reconstitution in HIV/AIDS patients after
HAART.
Not applicable Unknown CT00974454
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Current approaches towards production of anti-
HIV and TB agents isolated from plant
secondary metabolites
Crude extraction and/or isolated compound from the source
plants evaluate for their anti-HIV and TB properties. However,
these plants may have not been domesticated and their popu-
lation maybe limiting. Additionally, the slow growth rate of
source plants may significantly decrease the production of active
natural products. The low concentration of active molecules in
source plants as well as poor recovery of such compounds after
extraction also contributes to production challenges. Then, the
large scale of the source plants biomass is required to meet the
demands of drug manufacturing. This scenario could cause
massive damage on plant species and dramatically accelerate
their extinction. Therefore, naturally available production capacity
for compounds with anti-HIV and anti-TB activity is not sufficient
to meet the demands of commercial development. In this
context, plant cell cultures have emerged as sustainable and
controllable technology for commercial production of active
molecules. Advances in cell line selection, medium optimization,
biotransformation, feeding precursors, hairy root cultures, pro-
duct secretion, cell permeabilization and scale-up increased plant
natural products yield (Habibi et al., 2017a, 2018a). The devel-
opment of efficient, strong and novel ‘omics’ technologies such
as next-generation sequencing intensified plant cell culture
system and in this regard the number of companies using plant
cell cultures for the production of active natural products
continues to rapidly expand (Ochoa-Villarreal et al., 2016). This
technique has been successfully used for the production of
calanolides in a callus culture of C. brasiliense (Bernabe-Antonio
et al., 2010) and also artemisinin in hairy root cultures of
Artemisia annua L. (Ahlawat et al., 2014). Moreover, the emer-
gence of cambial meristematic cells could significantly circumvent
potential difficulties related to low yields, instability of product
yield, a relatively slow growth rate, industrial scale-up and
downstream processing (Ochoa-Villarreal et al., 2015). This
technology has been implemented for the production of gin-
senosides with yield of 268 mg/kg (Lee et al., 2010). Previously,
the anti-HIV effect of ginsenosides alone or in combination with
zidovudine monotherapy or HAART therapy has been demon-
strated (Im et al., 2016).
Beside these advances, progress in genome manipulation
resulted in relatively large quantities of pharmaceuticals. Metabolic
engineering is a promising strategy to obtain adequate active
compounds for industrial applications. Since, this technology is
related to the modification of cellular activities through the
manipulation of enzymatic, transport and regulatory functions of
the cell, those bottlenecks associated with commercial production
of active compounds such as slow growth of plant, genetic
instability, low concentration of end products, geographical
position and climatic conditions can be removed. Metabolic
engineering can boost productivity through increasing the cell
number production and improve the carbon flux by a biosynthetic
pathway via overexpression of genes. The main advantage of this
strategy is that it can offer a continuous and reliable source of active
secondary metabolites. In the metabolic engineering for the
production of plant secondary metabolites, identification of the
biosynthetic pathways of desired compounds, rate-limiting steps
and enzymes involved in reaction is required (Hussain et al., 2012).
However, the present knowledge in biosynthetic pathways in
plants is often still in its infancy and then development of strategies
based on cellular and molecular information is imperative. More-
over, the emergence of novel techniques of molecular biology, so
as to produce transgenic cultures and also to impact the expression
and regulation of biosynthetic pathways, is one of the critical steps
towards making plant cell culture as a sustainable and reliable
source for commercial production of active compounds.
Plant molecular pharming related to HIV and TB
Advantages and obstacles
In the past two decades, plant genetic engineering technologies
have shown substantial progress for the production of pharma-
ceutical products. Plant-based pharmaceutical production has
gained specific attention due to numerous advantages that are
equivalent or more beneficial compared with those of standard
expression systems (Daniell et al., 2015; De Martinis et al., 2016).
Table 4 Synergistic activity of medicinal plant with anti-TB drugs. (Gupta et al., 2017)
Plant names Agents Antibiotic
Fold reduction in
MIC of anti-TB drug FIC index References
E. natalensis 7-methyljuglone Isoniazid
Rifampicin
4–6 0.2
0.5
Bapela et al. (2006)
Galenia africana (E)-3,20,40-trihydroxy-30-
methoxychalcone,
(2S)-5,7,20-trihydroxyflavanone
Isoniazid1
Isoniazid
16
4
0.12
0.5
Mativandlela et al. (2009)
Commercial
source (plant origin)
oleanolic acid (OA) Isoniazid
Rifampicin
Ethambutol
4–16
8–16
4–16
0.121–0.347
0.113–0.168
0.093–0.266
Ge et al. (2010)
Piper nigrum L. Trans-trans isomer of 1-piperoyl-
piperidine (piperine)
Isoniazid
Rifampicin
8
4–8
0.25
<0.5
Sharma et al. (2010)
Knowltonia
vesicatoria (L.f.) Sims
Trans-trans isomer of 1-piperoyl-
piperidine (piperine)
Isoniazid 8 0.25 Labuschagne et al. (2012)
Notopterygium incisum Isoimperatorin (IO) Isoniazid
Rifampicin
4–6
5–20
0.2
0.133–0.472
Guo et al. (2014)
Mutellina purpurea L. Bisabolol
(R)-limonene
Rifampicin 16 0.0625–0.125
0.125–0.25
Sieniawska et al. (2015)
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Like yeast and mammalian cells, plants have the cellular machin-
ery needed to promote the post-translational modifications
required to glycosylate and fold proteins with the highest fidelity,
and unlike mammalian and bacterial cells, plants are devoid of
human pathogens and bacterial endotoxins. Additionally, plants
provide high biosynthesis capacity with low production cost in the
form of fresh leafy cells and edible seeds. The latter offer a further
benefit for the stable storage and transportation of target
proteins over long periods of time as well as high protein
accumulation (Vamvaka et al., 2016a, 2018; Yao et al., 2015). In
contrast, the downstream processing costs from traditional
systems remain a key concern in the production of recombinant
proteins, and edible plants can eliminate the need for these costly
purification processes as well as for cold chain processes for
transport and storage (Chan and Daniell, 2015; Kwon et al.,
2013a). Thus, plant-derived drugs can be produced efficiently in
developing countries without the need for expensive cold chain
and transport processes, which place an immense burden on the
healthcare system.
Two general strategies are available for expression of HIV and
TB recombinant proteins including (i) transient expression system
using viral or bacterial vector or combinations of therefore and (ii)
transgenic plants via nuclear or plastid expression. Compared to
expression of recombinant proteins in standard systems which
restricted to some specific host systems (e.g. E. coli, Pichia
pastoris and CHO cells), a range of plant species and different
expression strategies have been developed by academic and
industrial teams for the production of recombinant proteins.
Tobacco and its close relative N. benthamiana are widely used for
transient and stable production of recombinant proteins. In the
term of biomass production, it is estimated that high biomass
yields of up to 100 000 kg per hectare in open filed (Conley
et al., 2011) and 180 000 kg per year by vertical farming unit
(VFU) with a footprint of ~6500 m2 including ~2000 m2 (Holtz
et al., 2015) could be achieved by tobacco platform. N. ben-
thamiana also is the bioreactor of choice for large-scale produc-
tion of recombinant proteins in short period of time. Recently, by
the Caliber Biotherapeutics facility, it is feasible to grow more
than 4 million N. benthamiana plant at a single time in highly
automated multilevel growing environment under proprietary
LED lighting fixtures with biomass production per week ranged
from 3500 to 7000 kg (Holtz et al., 2015). Both of these plant
platforms have more substantial technical benefits over mam-
malian cell-based system including high-throughput screening
and development of target recombinant protein, available simple
process for both primary amino acid manipulation and glycosy-
lation engineering, and low-cost process for large-scale produc-
tion up to 150 kg of purified product per year (Holtz et al., 2015).
The presence of nicotine as a toxic alkaloid may restrict its oral
therapeutic applications; however, there are reports on the
development of new varieties of tobacco with low alkaloid which
are suitable for the production of recombinant proteins with the
potential of direct oral administration of plant tissue or crude
protein extracts (Joensuu et al., 2008), although FDA has not yet
approved any tobacco product for clinical applications. The use of
edible plants for oral administration could remarkably remove
prohibitively expensive fermentation, purification processes,
delivery, cold storage and transportation. Expression systems also
have been developed based on other plants such as rice, carrot,
maize, Spinach, lettuce (Chan and Daniell, 2015; Lakshmi
et al.,2013), cowpea, potato, Arabidopsis (Scotti et al., 2010)
and moss (Orellana-Escobedo et al., 2015) for the production of
recombinant HIV and TB antigens. Advantages and disadvantages
of these systems are reviewed elsewhere by Habibi et al. (2017b).
Besides the establishment of scalable unit operations, down-
stream processes have been optimized for efficient and afford-
able production of recombinant proteins. Different protocols
have been established for initial extraction of plant-based
recombinant proteins. These protocols have been designed based
on tissue and subcellular localization of accumulated protein. In
the case of secretion of recombinant protein in extracellular
compartments, protein recovery is easy, however encounter some
challenges related to protein degradation by plant cell proteases.
Recombinant proteins targeted to leaf or seeds organs are
generally extracted by blade-based homogenizers/screw presses
or mills, respectively (Buyel, 2018), following extraction buffer
within the pH range 5.0–8.0. However, protein extraction process
is eliminated when protein drugs bioencapsulated in plant cells
are orally delivered (Daniell et al., 2016a,b). In this context,
transplastomic plants can produce much higher levels of trans-
gene product (Boyhan and Daniell, 2011; Daniell et al., 2016a,b;
Kwon et al., 2013a; Ruhlman et al., 2010), enable delivery of
higher/more concentrated doses. Lyophilization further decrease
costs by increasing the concentration of therapeutic proteins,
which reduces the amount of material needed per dose (Kwon
et al., 2013a,b; Lakshmi et al.,2013; Shil et al., 2014; Su et al.,
2015a,b), allowing stable, long-term storage at ambient temper-
atures—sometimes for as long as two years—without loss of
efficacy, thereby breaking the cold chain barrier (Kwon et al.,
2013a,b; Lakshmi et al., 2013; Shil et al., 2014; Su et al., 2015a)
and eliminating microbial contamination.
Recombinant protein products for HIV
Broadly neutralizing antibodies
Broadly neutralizing antibodies (bNAbs) are a rare class of
antibodies that can develop in 15%–25% of people years after
the original exposure (Teh et al., 2014). Most bNAbs show
effective activity against HIV virus by disrupting viral replication via
immune exclusion or through Fc-mediated antibody activities
(Overbaugh and Morris, 2012). In the case of HIV-1 infection,
evidence from experimental animal models demonstrates that
bNAbs can inhibit HIV-1 acquisition (Teh et al., 2014). During
recent years, the monoclonal antibody therapeutics market has
grown significantly, that is it increased from $50 billion in 2010 to
nearly $90 billion in 2015, and this growth is predicted to reach
approximately $150 billion by 2021 (https://www.reportbuyer.c
om/product/5122216).
Mammalian cells are the gold standard expression system for
the majority of FDA-approved therapeutic antibodies (Lalonde
and Durocher, 2017). Given that the high potential of mam-
malian cells will not meet the demand, plants can be considered
an alternative strategy for the production of therapeutic anti-
bodies on a large economic scale. For instance, therapeutic mAbs
for one million patients who need one gram of product can be
produced in a 250 000 L fermenter (Ecker et al., 2015). How-
ever, this may not meet the need of global diseases, such as HIV/
AIDS. For HIV prevention, for example, a twice weekly dose of
30 mg mAb is recommended for women susceptible to HIV, and
this amount would correspond to more than 3 tons of mAb per
year for a million women (Buyel et al., 2017). The demand for an
efficient prophylactic approach could also escalate dramatically,
equalling ~50-100 tons of mAb per year, if we include the
HIV+ population (26 million in sub-Saharan Africa) and the at-risk
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population in entire countries or regions. The production of such
massive quantities of mAb with the currently used mammalian
cell culture platforms may not be feasible. CHO cells can
ultimately produce a maximum amount of 7.5 tons of mAb per
year under continuous and optimal operation (Kelley, 2007).
Moreover, the high investment cost required for CHO cell
medium ($US 14–22 million per batch for medium alone) and
reactor set-up as well as issues with contamination (Buyel et al.,
2017) are additional barriers that encourage the search for a cost-
effective and scalable platform.
In contrast to fermentation systems, plants can be scaled
efficiently and simply by sowing more seeds. In comparison with
that of CHO cells, the media cost for a plant expression platform
would be approximately $US 4.5 million assuming biomass yields
and fertilizer consumption (Buyel and Fischer, 2012). Moreover, in
the context of commercialization of process, the intrinsic yield
(i.e. the accumulation of product per unit biomass) is not as
crucial as the overall economy of the process (Fischer et al.,
2013). It means that upstream production in plant systems
benefits from scalability. On the other hand, increasing in the
number of plants producing target protein is not as expensive as
doubling the capacity of a fermenter facility (Fischer et al., 2013).
Therefore, the production of mAbs in a plant platform appears to
have benefits over a CHO cell fermenter in the upstream process;
however, the downstream capture and purification steps are
likely equivalent to those associated with CHO cells. The
purification steps using the protein A capture step are similar
for the manufacturing of all mAbs and typically include ion
exchange or hydrophobic interaction chromatography (Ma et al.,
2015). Moreover, the costs associated with formulation, cold
storage, transportation and sterile delivery are other concerns
that increase the cost of the end products. In this context,
economic models for commercial molecular farming based on
seed technology and/or oral delivery of vaccine bioencapsulated
in plant cells have been established to decrease the cost of
recombinant protein in term of downstream process, cold storage
requirements and sterile delivery.
Plant-based candidate vaccines against HIV
Despite 30 years of efforts to develop vaccines for eliciting
antibodies that can neutralize HIV-1 and confer protective
immunity, there is no FDA-approved vaccine (Klein et al.,
2013; McCoy and Weiss, 2013). The high genetic variability of
HIV and its capacity to escape the immune system resulted in
failure of effective vaccine development (Cohen, 2009). Hun-
dreds of clinical trials for HIV vaccine candidates have been
established, but none of them exhibited efficient and sufficient
effect on successfully neutralizing HIV to be approved for clinical
use (Esparza, 2013; Fauci and Marston, 2015; Haynes and
Mascola, 2017). Many attempts have been made to develop
new candidate vaccines based on protein subunits, DNA
vaccines, synthetic peptides, viral vectors expressing HIV-1 genes,
and attenuated and inactivated virus (Gamble and Matthews,
2011). However, the last two approaches were unsuccessful as
they showed poor protective efficacy. Several subunit vaccines
have been developed based on immunogenic HIV chimeric
proteins to elicit broad humuoral and cytotoxic CD8 + responses
and to protect against HIV (Rosales-Mendoza et al., 2012). Env
complex (gp120 and gp140), Gag, Tat and Nef proteins were
immunogenic, but Env complex is the only target protein, which
can induce neutralizing antibodies (NAbs) inhibiting viral entry.
However, Gag, Tat and Nef structures are able to elicit cellular
responses, which are involved in viral load blocking (Klasse et al.,
2012; Mascola and Haynes, 2013; Rosales-Mendoza et al.,
2015).
Several HIV candidate plant-based vaccines targeting early HIV
proteins and structural HIV proteins have been expressed in plants
using transient and stable expression systems. These candidates
are reviewed elsewhere (Rosales-Mendoza et al., 2015). The
combination of plant vaccine with other (or heterologous prime-
boost vaccination) could be advanced to elicit T-cell responses. In
this approach, the first vaccine is applied to ‘prime’ the elicitation
of antigen-specific T cells, consisting of a set of memory cells,
which endures beyond destruction of the antigen. On the other
side ‘boosting’ vaccine, targeting the same antigen(s) contributes
to elicit the extension of antigen-specific memory T cells (Webster
et al., 2005). Prime-boost vaccination strategy has been demon-
strated to increase the rate of antigen-specific CD4 + and
CD8 + T cells, improved high avidity T cells and consequently
boosted protective efficacy against pathogen invasion (Dalmia
and Ramsay, 2012; Shete et al., 2014). Plant-derived vaccines are
suitable for booster vaccines, specifically where the number of
doses is needed over long periods to induce and maintain
immunity, in population where reinfection occurs due to
environmental exposure. Proof-of-concept reports described in
mice have indicated the efficient use of plants cell in heterologous
prime-boost strategies (Daniell, 2019; Daniell et al., 2018; Lak-
shmi et al., 2013; Meador et al., 2017). However, in the absence
of such priming, plant cells are not suitable for vaccination against
infectious diseases (Chan et al., 2016; Daniell, 2019; Xiao and
Daniell, 2017).
Multi-epitope chimeric proteins are considered as promising
candidates for the development of HIV vaccines (Vasan and
Michael, 2012). In this context, the Env proteins gp120 and
gp140 are the main targets for the establishment of neutralizing
antibodies because these can bind to CD4 and its co-receptor on
CD4 + T lymphocytes. The application of multi-epitope chimeric
proteins enables viable immunization against non-immunodomi-
nant epitopes as well as the boosting of neutralizing antibodies
targeting Env (Forsell et al., 2009). The C4(V3)6 protein, a multi-
epitopic antigen composed of several V3 variants together with
the C4 domain of HIV, has been produced in both tobacco and
lettuce plants (Govea-Alonso et al., 2013a), and the oral admin-
istration of lettuce-derived C4(V3)6 elicited local and systemic
immune responses in mice (Govea-Alonso et al., 2013b), but HIV
viral neutralization was not evaluated.
Recently, Orellana-Escobedo et al. (2015) expressed multi-
epitope HIV proteins comprising epitope sequences from gp120
(C4 and V3) or four variants of the ELDKWA epitope from gp41 in
moss (Physcomitrella patens) plant and demonstrated that this
moss-derived HIV antigen is immunogenic in mice when subcu-
taneously administered and elicits humuoral responses against
the ELDWKA epitopes. However, neutralization of HIV was not
evaluated.
Lectins
Lectins such as griffithsin (GRFT), cyanovirin-N (CV-N) and
actinohivin (AH) are potential microbicide candidates against the
sexual transmission of HIV-1 which shows exquisite specificity to
high-mannose-type glycans on the viral envelope (Env) as well as
nanomolar neutralizing activity (O’Keefe et al., 2009, 2015;
Tanaka et al., 2009). These lectins have been produced by
different heterologous systems such as bacteria and yeast,
however, faced critical drawbacks such as inclusion body
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production following expensive and laborious re-solubilization and
refolding process by bacteria (O’Keefe et al., 2009). Hyper-
glycosylation by yeast resulted in protein dimerization and loss
of activity (Mori et al., 2002), and also the higher intrinsic cost
related to large-scale production. Additionally, the success of
lectin-based commercial products as topical and parenteral
microbicides for HIV depends on a bulk production system that
can provide high quantities of high-quality microbicides for
formulation and characterization (Fuqua et al., 2015). Upstream
and downstream processes as well as analytics programmes are
related to manufacturing costs in current good manufacturing
practice (cGMP) due to the need for quality control. These costs
can affect the overall cost of lectin manufacturing because these
microbicides are mostly required in resource-poor countries with a
high risk of HIV exposure. Consequently, these lectins, as a
microbicide, should be a low-cost recombinant protein (Fuqua
et al., 2015). In this context, transgenic plants are ideal systems for
low-cost and scalable production of recombinant proteins with
the potential for the direct preparation and application of crude
extracts (Stoger et al., 2014). Cereals such as rice and soybean are
efficient platform for the production of microbicides as they allow
high-level production of proteins in desiccated tissue, which
therefore intensify stability during transport and storage, and seed
extract inherently regarded safe as it is staple food crop (Sabalza
et al., 2013). In the term of downstream process, the ability of
production of protein body by cereals is a benefit as protein bodies
are insoluble in low-salt aqueous buffers, and they can be easily
purified by centrifugation. Particularly, this advantage could be
expanded by the production of recombinant proteins by rice
endosperm. Despite to other cereals, the presence of two different
protein bodies in rice endosperm enables expression of different
proteins simultaneously and facilitates their recovery by first
separating the compartments via density centrifugation (Vamvaka
et al., 2016a). This technology has been implemented for the
production of GRFT (223 lg/g dry seed weight) and CV-N (10 lg/
g dry seed weight) by Vamvaka et al. (2016a,b). However, in
contrast to other cereals such as maize, wheat and barley, the
content of rice seed is much lower, and the cost related to
growing is much higher.
Transient expression system has also been used for large-scale
production of lectins. For example, GRFT has been expressed
transiently in N. benthamiana using a vector based on tobacco
mosaic virus (TMV) resulted in the production of up to 1 g of
soluble GRFT per kg of fresh leaf weight (O’Keefe et al., 2009).
Previously, the production of GRFT has been reported in E. coli
with a yield of 819 mg/L, but only 66% of the protein was
present in the soluble fraction and the 34% was found in
inclusion bodies and was impossible to re-solubilize even using
detergents. However, the high cost of in vitro RNA transcription
used in transient expression of GRFT is a notable problem of virus-
based systems, and the purification of GRFT based on tobacco
mosaic virus (TMV) is considered to result in some contamination
with TMV coat protein and protein degradation, which would
result in the need for further purification steps (Habibi et al.,
2018b). We recently reported our efforts to optimize high-level
expression and purification processes for the production of GRFT
based on a non-viral expression vector, and our proposed process
was able to improve the recovery of GRFT using a one-step
protocol for purifying GRFT from crude extract (Habibi et al.,
2018b). This is comparable to GRFT produced in E. coli after
refolding, but neither re-solubilization nor refolding steps are
needed.
Recently, the new approach of combining neutralizing anti-
bodies with lectins as bispecific anti-HIV proteins against HIV
diversity has been developed. The wide diversity and high
mutation rate of the virus enable virus to evade monotherapy
rather quickly (De Mendoza, 2016). However, an optimal
combination therapy should consist of individual anti-HIV-1
component that synergistically works together and efficiently
inhibit the virus replication. In the last decades, several bispecific
anti-HIV agents have been produced and have been shown to
have ability to neutralize several strains (Bournazos et al., 2016;
Huang et al., 2016). In this context, the lectin actinohivin,
extracted from actinomycete bacteria, has been shown as a
promising candidate with high anti-HIV activity (Matoba et al.,
2010). The production and anti-HIV activity of one of such
bispecific entry inhibitors consisting of Avaren fused to the bNAb
VRC01 were reported recently (Kasinger et al., 2019). According
to this model, neutralizing activity against HIV strain was
enhanced. However, compared to the parental molecules
(~150 mg/kg for VRC01 (Hamorsky et al., 2013) and up to
100 mg/kg for Avaren (Kasinger et al., 2019)), fused VRC01Fab-
Avaren yield was lower and required three-step chromatography
purification procedure. Similarly, the combination therapy using
three microbicidal proteins 2G12, the GRFT and CV-N cocktail
produced in rice endosperm (Vamvaka et al., 2018). Extracts of
transgenic plants expressing all three proteins demonstrated
increased in vitro binding to gp120 and synergistic HIV-1
neutralization. Besides enhanced neutralizing activity, application
of crude seed extract directly can significantly eliminate expensive
purification process as the deployment of antibodies and lectins
as HIV-1 entry inhibitors is critically contingent on large-scale
inexpensive production.
Plant-derived vaccines against TB
Vaccines are the most efficient, affordable and least invasive
strategy to combat TB. Numerous efforts have focused on the
design and development of new candidates as anti-tuberculosis
vaccines. Approximately 25 novel and potent TB vaccine candi-
dates are in development and/or different stages of clinical trials
(http://www.tbvi.eu/what-we-do/pipeline-of-vaccines/) (Table 5).
Most of these vaccines are subunit vaccines, whereas others are
considered attenuated live TB vaccines. Compared with attenu-
ated live TB vaccines, subunit vaccines offer more advantages in
terms of safety and efficacy as well as standardization (Agger and
Andersen, 2001). Subunit vaccines can be categorized into two
groups: primary prevention vaccines (aiming to replace the
Bacillus Calmette-Guerin vaccine (BCG)) and booster vaccines
(intended for revaccination). The booster vaccines are required to
inhibit reactivation of the pathogen during latent tuberculosis
(Uvarova et al., 2013). ESAT-6, CFP10, Ag85B, MTB72F and LipY
are promising subunit candidates designed from surface compo-
nents and secreted proteins of TB (Lakshmi et al., 2013; Uvarova
et al., 2013). The latter is best suited for vaccine production
because antigenic proteins are actively secreted during the early
phase of the TB life cycle and can thus promote a strong T-cell
response and c-interferon secretion (Ben Amor et al., 2005;
Brodin et al., 2004; Gao et al., 2009). In general, any mycobac-
terial antigen that induces both CD4 and CD8 T cells and confers
protective immunity is a promising candidate for subunit vacci-
nation against TB.
The establishment and development of a potent vaccine that
boosts the immune response to tuberculosis at the mucosal level
is a challenge in the field of vaccine research. Previous studies
ª 2019 The Authors. Plant Biotechnology Journal published by Society for Experimental Biology and The Association of Applied Biologists and John Wiley & Sons Ltd., 17, 1868–1891
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have shown that novel mucosal administration strategies can
definitely boost vaccine efficacy due to local immuno-protective
responses at the respiratory system mucosa (TBVI Organization.
Available from: www. tbvi.eu/about-us/organization/ clinicalde-
velopment-team.html [Last accessed 12 September 2014]). Thus,
mucosal immunization strategies can remarkably contribute to
the establishment and development of improved vaccines.
However, vaccine formulations remain challenging due to the
high costs associated with antigen expression and purification.
Efficient and affordable vaccination approaches should rely on
low-cost production systems with facile delivery, which will
significantly facilitate massive immunization in limited recourse
settings, where the vaccine is urgently required (Rosales-Mendoza
et al., 2015). Different systems have been used for delivery of
subunit vaccines including recombinant bacterial vector system
(Triccas, 2010), recombinant viral vector system (Sereinig et al.,
2006) and lipoglycan–protein conjugate system (Hamasur et al.,
2003). However, the high cost of these systems, as well as
concerns related to patient safety particularly in terms of bacterial
(Yurina, 2018) and viral vectors, promoted plant-based delivery
system approach. By using the plant cell as the carrier, subunit
vaccines can be delivered through mucosal route such as oral
administration. The mucosal route is ideal because it is non-
invasive and more favourable. Moreover, oral vaccination routes
do not need special skills and remove disadvantages related to
syringe-based injection or other required invasive procedures. As
Mtb is a respiratory pathogen, vaccination through mucosal route
can elicit both mucosal and systemic immune system responses
(Cong et al., 2014). Additionally, bioencapsulation of subunit
vaccine into plant cell is advantageous as plant cell protect
antigens from harsh environments and enzymatic reactions in the
gut (Arlen et al., 2008).
However, antigen entry from the intestine to the immune or
circulatory system needed fused carrier proteins such as E. coli
cholera toxin B (CTB) subunit (Limaye et al., 2006; Xiao et al.,
2016). Functional CTB is pentameric and interacts with GM1
ganglioside, which is available in membranes of intestinal
epithelial cells, neurons and immune cells, among others (Limaye
et al., 2006). It has been demonstrated that the adjuvanticity of
CTB enhances when fused with foreign antigens. This could
potentiate better uptake of antigen across the mucosal linings
and provide sufficient antigen for dendritic cells and macro-
phages and then boost systemic and mucosal immune response.
This concept has been used for range effective subunit booster
vaccine in plant system, and results showed protective immunity
against disease states (Arlen et al., 2008; Daniell, 2019; Daniell
et al., 2018; Davoodi-Semiromi et al., 2010; Ruhlman et al.,
2007a). Following priming with BCG, oral administration of plant-
based booster vaccines is efficient strategy to elicit mucosal as
well as systemic immunity. Chloroplast-derived vaccine candidate
including CTB-ESAT6, CTB-Mtb72F and LipY fusion protein has
been efficiently used in oral boost treatment regimen (Lakshmi
et al., 2013).
Critical factors involved in practical development of oral plant
vaccines include adequate level antigen production, for immu-
nization, stability, storage and vaccine efficacy. In relation to
antigen expression, tobacco plants are ideal platform for large-
scale production. It was reported that 80 mg of CTB-ESAT6 can
be produced from a single tobacco plant and a total of 1.92 kg
can be obtained from an acre of land based on three cuttings in a
year (Lakshmi et al., 2013). For some commercial tobacco
cultivars with high-level production, antigen yield is predicted to
be much higher. As described above, cost of end product by oral
administration of edible plant-based subunit vaccines would be
much lower. Based on human trails, it was demonstrated that
50 lg of subunit vaccine ESAT-6 is required to promote strong
and long-lasting Mtb specific T-cell responses. The expression of
CTB-ESAT6 following lyophilization resulted in increasing of
antigen to 249 lg/g of lyophilized leaves, requiring only
200 mg plant powder for oral immunization to maintain protec-
tive immune response. Lettuce plants were chosen as an
alternative system to tobacco plant for the production of TB
antigen candidate as they are leafy vegetables and have suitable
properties. Several vaccine antigens and biopharmaceuticals have
been expressed and validated in transplastomic lettuce plants
(Daniell, 2019; Daniell et al., 2016a,b; Su et al., 2015a).
Conclusion
TB and AIDS are high-burden diseases that lead to death
worldwide and place a major burden on the public health system,
particularly in resource-limited settings. Combined with the
growing population in developing countries with high burden
of HIV and TB, this will increase the demand for anti-HIV and TB
agents. Biotechnological processes are required to supply such
agents, but established production systems such as those based
on microbes and mammalian cell cultures are unlikely to fulfil
expectations related to this urgent need because of the expensive
production costs and the inherent complexity and toxicity of anti-
HIV and TB agents. In this context, plants provide an efficient and
affordable platform to fill this gap because they can produce a
large number of agents with anti-HIV and TB activity. Plant
natural product and/or plant extracts with killing potential are
promising approaches to tackle the prevention and control of
both diseases. Some plants have been shown to be promising
sources of anti-TB and HIV drugs because they effectively inhibit
both pathogens at very low concentration, which is important in
terms of drug-related toxicity during long-term treatment.
However, isolation, purification and identification of target
compounds from complex crude extracts are complicated. The
production of materials with uniform levels of active ingredients
in native plants is a major challenge. Moreover, the validation of
the efficacy and safety of plant-based compounds is the most
important issue, which needs rigorous clinical evaluation.
Using plants as vaccine biofactories and orally administration
by edible plants have been shown as a promising strategy to elicit
both systemic and mucosal immune responses. However, par-
enteral formulations require extensive purification and expensive
cold storage/transportation. In contrast, orally administration can
be obtained by convenient lyophilization of plant biomass
expressing the target protein. Methods are readily available for
growth of plants in FDA-approved hydroponic growth facilities,
lyophilization, drug dose determination, evaluation of stability
upon long-term storage at ambient temperature, oral delivery of
antigens to the immune system and evaluation of immune titres
and protection against pathogen or toxin challenges. However,
orally delivered plant antigens without injectable priming results
in inducing tolerance rather than immunity (Daniell et al., 2016a,
b; Herzog et al., 2017; Su et al., 2015a,b). Therefore, vaccine
antigens made in plant cells can only function after injectable
priming (Chan et al., 2016; Daniell, 2019; Xiao and Daniell,
2017). This approach is suitable where injectable vaccine is not
affordable for a large majority of global population and a low-
cost booster vaccine is needed (like polio booster vaccine). In the
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context of HIV, there is no approved injectable vaccine and
therefore boosting via plant cells is not currently feasible.
However, oral boosting with antigens made in plant cells against
TB after BCG vaccine priming is feasible and beneficial because of
generation of both mucosal and systemic immunity. Boosting is
urgently needed to maintain immunity in global regions where
reinfection rate is very high and mucosal immunity conferred by
oral antigens is essential to deal with pathogen at the site of
entry.
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